ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1803

Genetics of eGFR Variability as a Proxy for Lupus Nephritis in Patients with Systemic Lupus Erythematosus

Magdalena Riedl Khursigara1, Nicholas Gold2, Thai-Son Tang3, JingJing Cao4, Daniela Dominguez4, Marisa Klein-Gitelman5, Dafna Gladman6, Daniel Goldman7, Elizabeth Harvey4, Mariko Ishimori8, Caroline Jefferies9, Diane Kamen10, Sylvia Kamphuis11, Andrea Knight12, Chia-Chi Lee13, Deborah Levy2, Damien Noone4, Karen Onel14, Christine Peschken15, Michelle Petri7, Janet Pope16, Eleanor Pullenayegum4, Earl Silverman17, Zahi Touma18, Murray Urowitz19, Daniel Wallace20, Joan Wither21 and Linda Hiraki2, and Systemic Lupus Erythematosus Collaborative Clinics (SLICC), 1University of Toronto, Cambridge, MA, 2The Hospital for Sick Children, Toronto, ON, Canada, 3University of Toronto, Mississauga, ON, Canada, 4The Hospital for Sick Children, Toronto, Canada, 5Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 6University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 7Johns Hopkins University School of Medicine, Timonium, MD, 8Cedars-Sinai Health System, Los Angeles, CA, 9Cedars-Sinai Medical Center, Beverly Hills, CA, 10Medical University of South Carolina, Charleston, SC, 11Erasmus University Medical Center, Rotterdam, Netherlands, 12Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 13Cedars-Sinai Medical Center, Los Angeles, CA, 14HSS, New York, NY, 15University of Manitoba, Winnipeg, MB, Canada, 16University of Western Ontario, London, ON, Canada, 17Silverman, Toronto, ON, Canada, 18University of Toronto, Toronto, ON, Canada, 19Self employed, Toronto, ON, Canada, 20Cedars Sinai Medical Center, Studio City, CA, 21University Health Network, Toronto, ON, Canada

Meeting: ACR Convergence 2024

Keywords: Genome Wide Association Studies, Lupus nephritis, Pediatric rheumatology, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: SLE – Etiology & Pathogenesis Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Lupus nephritis (LN) is one of the most common and severe manifestations of systemic lupus erythematosus (SLE). We performed genome wide association studies (GWAS) for lupus nephritis and kidney function measures over time. We hypothesized that analyzing a person’s eGFR variability over time would be a good proxy for LN and improve power for detecting genetic loci for LN. We also used local ancestry estimation to facilitate inclusion of admixed individuals and generate ancestry specific estimates for LN outcomes.

Methods: We included SLE patients from several child and adult dedicated lupus databases and the Systemic Lupus International Collaborating Clinics (SLICC) cohort. All met American College of Rheumatology and/or SLICC SLE classification criteria and were genotyped on a multi-ethnic Illumina array. Ungenotyped SNPs were imputed to the Trans-Omics for Precision Medicine program (TopMed), and local ancestry of chromosomal information was estimated using RFMix and Tractor software. LN was defined by SLE criteria, with a subset confirmed by kidney biopsy. Kidney function (estimated glomerular filtration rate, eGFR) was calculated using the Schwartz Bedside formula for measures < 18 years and CKD-EPI for >18 years of age. Wilcoxon rank sum or Chi-square tests were used to compare characteristics such as kidney function between LN and Non-LN patients. We completed separate GWAS for the outcomes of LN, mean eGFR and eGFR variability over time (log of the mean absolute deviation from mean eGFR per participant), in marginal and multivariable adjusted regression models with sex, site and local principal components using Regenie. Local ancestry analysis was restricted to individuals of European, African and East Asian ancestry using Tractor. We meta-analyzed ancestry-specific results with METAL software (significance p< 5x10-8).

Results: We studied 2981 individuals with SLE, 88% female, 46% of European ancestry, 27% childhood-onset SLE, and 45% with LN (Table). Kidney failure was observed in 25 patients over a median follow-up time of 8.9 years (IQR: 4.1,14.8). Within-person eGFR was similar between people with and without LN, but eGFR variability was significantly greater in people with LN (P-value= 2.2e-16). Variability was calculated using a median of 16 [IQR: 8,35] eGFR measurements per person. GWAS of LN did not identify a significant LN locus, yet GWAS of eGFR variability demonstrated a significant peak on chromosome 15, downstream of SCH4 and intronic to SECISBP2L (Figure). The variant was found in a genomic region of African ancestry.

Conclusion: We completed GWAS of LN, eGFR mean and variability over time, generating ancestry specific estimates and identified a genome-wide significant locus for variability in measures of renal function over time, in a multiethnic cohort of children and adults with SLE. This locus was only found in an African ancestry portion of the genome. Variability in measures of renal function is correlated with LN, yet GWAS of LN did not identify significant loci. Future work includes repeating analyses to include all global ancestries, and to investigate the biologic link between the loci and LN.

Supporting image 1

Table: Characteristics of LN and Non-LN patients (* data available for N= 2740, ** time in years)

Supporting image 2

Figure: Manhattan Plot for eGFR variability. Significant locus on chromosome 15 (red square). Red line indicates cut-off for significance of 5×10-8.


Disclosures: M. Riedl Khursigara: None; N. Gold: None; T. Tang: None; J. Cao: None; D. Dominguez: None; M. Klein-Gitelman: AbbVie/Abbott, 2, AstraZeneca, 2, Eli Lilly, 1; D. Gladman: AbbVie, 2, 5, Amgen, 2, 5, AstraZeneca, 2, BMS, 2, Celgene, 2, 5, Eli Lilly, 2, 5, Galapagos, 2, 5, Gilead, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5; D. Goldman: None; E. Harvey: None; M. Ishimori: None; C. Jefferies: Amgen, 11, Eli Lilly, 5, 11, Takeda, 3; D. Kamen: Alpine Immune Sciences, 1, Bristol Myers Squibb (BMS), 1; S. Kamphuis: None; A. Knight: Pfizer, 6; C. Lee: None; D. Levy: AbbVie, 5, AstraZeneca, 5, Roche, 5, SOBI, 5; D. Noone: None; K. Onel: None; C. Peschken: AstraZeneca, 1, GlaxoSmithKlein(GSK), 1, Roche, 1; M. Petri: Amgen, 2, AnaptysBio, 2, Annexon Bio, 2, Arthros-FocusMedEd, 6, AstraZeneca, 2, 5, Atara Biosciences, 2, Aurinia, 5, 6, Autolus, 2, Avoro Ventures, 2, Biocryst, 2, Boxer Capital, 2, Cabaletto Bio, 2, Caribou Biosciences, 2, CTI, 1, CVS Health, 1, Eli Lilly, 2, 5, Emergent Biosolutions, 1, Ermiium, 2, Escient Pharmaceuticals, 2, Exagen, 5, Exo Therapeutics, 2, Gentibio, 2, GlaxoSmithKlein(GSK), 2, 5, iCell Gene Therapeutics, 2, Innovaderm Research, 2, IQVIA, 1, Janssen, 5, Kira Pharmaceuticals, 2, Merck/EMD Serono, 1, Nexstone Immunology, 2, Nimbus Lakshmi, 2, Novartis, 2, PPD Development, 2, Precision Biosciences, 2, Proviant, 2, Regeneron Pharmaceuticals, 2, Sanofi, 2, Seismic Therapeutic, 2, Senti Bioscienes, 2, Sinomab Biosciences, 2, Takeda, 2, Tenet Medicines Inc, 2, TG Therapeutics, 2, UCB, 2, Vertex Pharmaceuticals, 2, Worldwide Clinical Trials, 1, Zydus, 2; J. Pope: None; E. Pullenayegum: None; E. Silverman: None; Z. Touma: None; M. Urowitz: None; D. Wallace: None; J. Wither: AstraZeneca, 1, 2, Pfizer, 5; L. Hiraki: Janssen, 2.

To cite this abstract in AMA style:

Riedl Khursigara M, Gold N, Tang T, Cao J, Dominguez D, Klein-Gitelman M, Gladman D, Goldman D, Harvey E, Ishimori M, Jefferies C, Kamen D, Kamphuis S, Knight A, Lee C, Levy D, Noone D, Onel K, Peschken C, Petri M, Pope J, Pullenayegum E, Silverman E, Touma Z, Urowitz M, Wallace D, Wither J, Hiraki L. Genetics of eGFR Variability as a Proxy for Lupus Nephritis in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/genetics-of-egfr-variability-as-a-proxy-for-lupus-nephritis-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genetics-of-egfr-variability-as-a-proxy-for-lupus-nephritis-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology